US Patent

US11337967 — Methods of treatment

Method of Use · Assigned to Bow River LLC · Expires 2037-05-16 · 11y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent provides methods for treating a patient with a CYP3A4 substrate drug after stopping posaconazole treatment.

USPTO Abstract

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4123 — larotrectinib-sulfate
U-4123 — larotrectinib-sulfate
U-4123 — larotrectinib-sulfate

Patent Metadata

Patent number
US11337967
Jurisdiction
US
Classification
Method of Use
Expires
2037-05-16
Drug substance claim
No
Drug product claim
No
Assignee
Bow River LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.